Core Insights - Merck & Co., Inc. (NYSE:MRK) is recognized as one of the 15 Best Stocks to Buy for the Medium Term [1] - BofA analyst Tim Anderson raised the price target for Merck to $105 from $98 while maintaining a Buy rating, highlighting the potential of the Cidara deal and its alignment with Merck's Infectious Disease franchise [2] - In Q3 2025, Merck reported revenue of $17.3 billion, a 4% increase year-over-year, with KEYTRUDA sales growing 10% to $8.1 billion, and expects total revenue to reach between $64.5 billion and $65 billion [3] - New product approvals contributed to growth, with Winrevair generating $360 million in Q3 and Capvaxive reporting $244 million in sales, alongside a strong pipeline of over 80 active clinical trials [4] - The animal health segment also saw a 9% year-over-year sales increase to $1.6 billion, driven by rising pet-related spending [5]

Foreign reserve managers could reduce their holdings of French government debt by €70 billion ($81 billion) after a spate of credit-rating downgrades, according to BofA analysts https://t.co/4BoZcstFAN ...

Investors can best play the tech frenzy by mixing AI names with holdings of cheaper stocks linked to the economy, BofA strategists say https://t.co/yGMz9LukeW ...

Mastercard's global policy head Jesse McWaters called the GENIUS Act a “turning point” for mainstream stablecoin adoption, citing increased regulatory clarity and institutional confidence. He noted that regulated entities can now issue USD-backed stablecoins, with major firms like JPMorgan, Citi, BofA, Amazon, and Apple already advancing plans. “Mastercard has been preparing for this,” he added.https://t.co/Z2Zxu86aSe ...